X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!
















Authors
 

Novartis vs Indian Patents Act - Case decoded

(Apr 5, 2012)

This article describes the case of Novartis' Glivec against the Indian Patent Act.

Novartis: Growth not visible

(Oct 30, 2004)

MNC pharma company, Novartis India, declared its 2QFY05 and 1HFY05 results yesterday. The topline of the company has registered a marginal growth in the quarter. However, the bottomline saw a decline of 18% owing to lower other income and higher tax expenses on a YoY basis. The poor performance of the bottomline is despite an operating margin expansion of 780 basis points.

Novartis: Dismal performance continues

(Oct 31, 2003)

MNC pharma major, Novartis, announced dismal 2QFY04 results yesterday. The company has reported a 5% drop in topline and a 17% decline in bottomline. For 1HFY04, while the net sales have dropped marginally, pressure on margins has resulted in a 9% drop in net profits. In this context, let us briefly evaluate the company’s performance during the period under review.

Identifying an MNC pharma stock: Do's and don'ts

(Oct 11, 2003)

In Views on News, Equitymaster has tried to highlight here some factors one should keep in mind before investing in an Pharmaceuticals company. Know more

Novartis: Dwindling margins

(Aug 11, 2003)

MNC pharma major, Novartis announced its 1QFY04 results recently. While the company has recorded a marginal growth in topline, the operating profits have seen a 25% drop. However, sharp rise in other income and lower tax provisions have helped Novartis register a 6% growth in the bottomline. In this context, let us briefly evaluate the performance of the company.

Novartis: OPM under pressure

(Oct 25, 2002)

Novartis India has posted a net profit of Rs 318 m for 2QFY03, a rise of 48% over corresponding quarter last year. As against Rs 216 m in the corresponding quarter last year. However, the figures for the year are not comparable as the company demerged its agrochemical business, which resulted in this sharp decline in turnover and profits. The company also decided to exit the lens and lens care business of CibaVision with effect from December 2000 due to unviability of the same. The other income

Novartis: Margins improve, sales lacklustre

(May 2, 2002)

Novartis India has ended FY02 on an encouraging note. While sales represent a 7% rise, net profit has grown at a faster pace thanks to a rise in operating margins, lower interest cost and positive impact from the closure of the loss making Ciba Vision operations. A sustained rise in margins for all the four quarters of the current year was ensured on the back of better price realisations, control over input costs and re-launch of its key brands.

Novartis: Margins on upward spiral

(Jan 28, 2002)

Novartis India has declared encouraging results for 3QFY02. Net profits have leapfrogged by more than 100% on a back of sharp spurt in operating margins. However, the growth in topline has slowed down considerably with just 2% growth in the concerned quarter. Subsequent to completion of the demerger of its agribusiness and amalgamation of Ciba CKD Biochem, the company has recast prior period results. The results are thus comparable on a year to year basis.

Novartis India: An update

(Nov 9, 2001)

Novartis India has gone through a major restructuring exercise in the last one year. The company has hived off/ discontinued its loss making businesses and vertically integrated its operations. The results of the same are now becoming apparent.

Novartis: Restructuring benefits visible

(Oct 31, 2001)

Novartis India has announced a 6.8% growth in sales and 38% growth in PBT for 1HFY02. Subsequent to completion of the demerger of its agribusiness and amalgamation of Ciba CKD Biochem, the company has recast prior period results. The results are thus comparable on a year to year basis.

Novartis: Operating margins disappoints

(Jul 27, 2001)

Novartis India has posted a net profit of Rs 92 m for 1QFY02 as against Rs 186 m in the corresponding quarter last year. However, the figures for the year are not comparable as the company demerged its agrochemical business, which resulted in this sharp decline in turnover and profits. The company also decided to exit the lens and lens care business of CibaVision with effect from December 2000 due to unviability of the same.

Novartis FY01 net at Rs 526 m

(Jun 29, 2001)

Novartis India has posted a net profit of Rs 526 m for FY01 as against Rs 1,034 m for FY00. However, the figures for the year are not comparable as the company demerged its agrochemical business, which resulted in this sharp decline in turnover and profits. Again, in the current year, the management also decided to exit the lens and lens care business of CibaVision with effect from December 2000. This is based on the ground that the business did not reach a critical mass within a reasonable peri

Agro hive off masks Novartis’ Q3 net

(Jan 18, 2001)

Novartis India Ltd has posted a net profit of Rs 121.9 m for the quarter ended December 31, 2000 as against Rs 323.80 m for the corresponding period. The turnover in the current quarter stands at Rs 1,141 m as against the figure of Rs 2,340 m in the corresponding period of last year. It must however be kept in mind that the company demerged its agrochemical business in the current year and this accounts for the reduction in the turnover and profits. The company has however not given out the corr

Novartis: In need of ‘calcium sandoz’

(Dec 8, 2000)

Novartis held an analyst meet yesterday to apprise investors of the latest developments after the hive off the agri business operations. The management announced a takeover of the Ciba CKD, a joint venture with a Korean company, elaborated on the realignment of its ophthalmic business and expressed its intent to divest the remaining portion of its Goregaon (a Mumbai suburb) property.

Novartis: Agribusiness pulls down margins

(Nov 14, 2000)

A bad performance by the agro chemicals division has put pressure on Novartis' profitability in the second quarter of the current year. While turnover has slipped 8%, the net profit has crashed over 33%. The company has infact clarified that of its agribusiness contributed 53% of its turnover but 32% of its pre–tax profits for the first half of the current year.

Novartis: Demerger dose takes effect

(Nov 14, 2000)

The Novartis stock has been at the receiving end over the past one week. The stock hit a 52 week low of Rs 501 yesterday. The primary reason seems to be the adjustment for the spin off of its agrochemical unit. This is in line with the proposal of its international parent Novartis AG to separate its agrochemical arm. This would then be merged with the agrochemical arm of Astra Zeneca to form a new company Syngenta. In India too the same process is underway.

Novartis consolidates post spin off

(Aug 23, 2000)

An over 40% rise in the stock price (over two months) is the market’s way of looking at the spin off of the agrochemical division by Novartis India. (The international parent Novartis AG has proposed the separation of its agrochemical arm and its merger with the agrochemical arm of Astra Zeneca to form a new company Syngenta. In India too the same process is underway.)

Novartis India: Outpaces industry once again

(Jul 29, 2000)

A 12% growth in the topline has led to a commensurate growth in the bottomline for Novartis India. While the operating margins have improved, higher depreciation has nullified the rise in operating margins.

Life Sciences Companies divorce agrochem operations

(Jul 14, 2000)

The wheel seems to have come a full circle for life science companies. The last year has seen an across the board spin off of their agro–chemical arms by the life science (a euphemism for a conglomerate of pharmaceutical and agrochemical operations) corporations.

Creditable results from Novartis

(May 31, 2000)

Novartis has reported a 38% growth in its annual net profit on the back of a 10.3% growth in its topline.


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS